Opko will acquire a 45% stake in an undisclosed private Israeli company from FDS Pharma, which manufactures active pharmaceutical ingredients (APIs) for Russia and other markets. The Israeli company produces a third-generation HBV vaccine called...

Dong Sung received an exclusive, seven-year license to market and distribute Generex's Generex Oral-lyn insulin spray delivered via RapidMist technology in South Korea. SciGen Ltd. (ASX:SIE, Singapore), which previously received a non-exclusive license to market...

SciGen received rights to market and distribute Generex's Generex Oral-lyn insulin spray delivered via RapidMist technology in China, Hong Kong, Indonesia, South Korea, Malaysia, the Philippines, Singapore, Thailand and Vietnam. SciGen will be responsible for...

The companies will use NSVX's VaxiSome platform and SIE's hepatitis B antigen to develop and market an intranasal vaccine to treat HBV. The partners will split development costs and future revenues, starting with an Israeli...

The companies signed a memorandum of understanding under which SIE will acquire Shreya's GMP biological manufacturing facility in Pune, India. Shreya was previously SIE's contract manufacturer for biotech products. SciGen Ltd. (ASX:SIE), Singapore Shreya Group...

Bioton S.A. , Warsaw, Poland SciTech Genetics Pte Ltd. , Singapore Business: Gastrointestinal, Endocrine SciTech agreed to sell its 19.17% stake in SciGen Ltd. (ASX:SIE, Singapore) to Bioton. Bioton will purchase 105.7 million SIE shares from SciTech...

Intercell and SIE will co-develop an HBV vaccine that combines SIE's Sci-B-Vac PreS1- and PreS2- HBV antigen with Intercell's Immunizer IC31 adjuvant. The companies will share development costs and will jointly own resulting products. Intercell...

Intercell (Vienna, Austria) and SciGen (ASX:SIE) will co-develop an HBV vaccine that combines SIE's Sci-B-Vac PreS1- and PreS2- HBV antigen with Intercell's Immunizer IC31 adjuvant. The companies will share development costs and will jointly own...

GENIZ completed its tender offer for the 2.1 million SCGN shares outstanding at $14 per share (see BioCentury Oct. 16). SCGN is now a wholly owned subsidiary of GENIZ. Genetics Institute Inc. (GENIZ), Cambridge, Mass....